4579 RaQualia Pharma Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4579

TSE Growth

RaQualia Pharma Inc.

1,129

JPY

-131

(-10.40%)

Dec 5, 3:30 pm JST

7.30

USD

Dec 5, 1:30 am EST

Result

PTS

outside of trading hours

1,101

Dec 5, 11:58 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	2,776	707	863	755	36.1	0	Feb 14, 2022	J-GAAP
Dec, 2022	2,918	866	904	723	34.5	0	Feb 14, 2023	J-GAAP
Dec, 2023	1,901	-337	-293	-323	-15.0	0	Feb 14, 2024	J-GAAP
Dec, 2024	3,107	-213	-361	-495	-22.9	0	Feb 14, 2025	J-GAAP
Dec, 2025 Guidance	3,888	118	73	-71	-2.9	0	Feb 14, 2025	J-GAAP
YoY	+25.1%	－	－	+85.7%	+87.3%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2020	Feb 14, 2020	2,129	70	85	13	0	J-GAAP
	Aug 14, 2020	1,579	-260	-256	-333	0	J-GAAP
	Dec 28, 2020	852	-753	-759	-843	0	J-GAAP
	Feb 2, 2021	1,107	-486	-527	-606	0	J-GAAP
Results	Feb 12, 2021	1,107	-486	-527	-606	0	J-GAAP
Dec, 2021	Feb 12, 2021	Available in future release
	Jun 30, 2021
	Dec 20, 2021
Results	Feb 14, 2022
Dec, 2022	Feb 14, 2022
	Nov 17, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
	Dec 8, 2023
Results	Feb 14, 2024
Dec, 2024	Feb 14, 2024
	Dec 13, 2024
Results	Feb 14, 2025
Dec, 2025	Feb 14, 2025	3,888	118	73	-71	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2008	0	－	Available in future release
Dec, 2009	0	－
Dec, 2010	1,186	－
Dec, 2011	684	-42.3
Dec, 2012	28	-95.9
Dec, 2013	228	+714.3
Dec, 2014	153	-32.9
Dec, 2015	145	-5.2
Dec, 2016	705	+386.2
Dec, 2017	1,419	+101.3
Dec, 2018	744	-47.6
Dec, 2019	1,702	+128.8
Dec, 2020	1,107	-35.0
Dec, 2021	2,776	+150.8
Dec, 2022	2,918	+5.1
Dec, 2023	1,901	-34.9
Dec, 2024	3,107	+63.4
Dec, 2025 Guidance	3,888	+25.1	118	－	73	－	-2.9	+87.3

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	1,901	-337	-18	-5.58	-4.92	0.29	-15.0
Dec, 2024	3,107	-213	-6.9	-8.51	-5.99	0.38	-22.9
Dec, 2025 Guidance	3,888	118	3.03	-1.18	-0.75	0.41	-2.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	3,107	866	904	755	36.1
Fiscal Year	Dec, 2024	Dec, 2022	Dec, 2022	Dec, 2021	Dec, 2021

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	1,471	315	223	254	12.1	0	Feb 14, 2023	J-GAAP
Jul - Dec, 2023	887	-314	-329	-348	-16.1	0	Feb 14, 2024	J-GAAP
Jul - Dec, 2024	1,696	-59	-84	-172	-8.0	0	Feb 14, 2025	J-GAAP
Jul - Dec, 2025 Guidance	2,353	308	364	283	11.6	0	Aug 14, 2025	J-GAAP
YoY	+38.7%	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	866	1,433	1,480	-47	-29	3,679	58.80	J-GAAP
Dec, 2023	-337	-853	-718	-135	793	3,664	53.33	J-GAAP
Dec, 2024	-213	-3,485	180	-3,665	2,982	3,141	32.53	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	1,495	-108	-36	-117	-5.5	ー	Nov 10, 2023	J-GAAP
Jan - Sep, 2024	2,369	-27	-231	-339	-15.7	ー	Nov 14, 2024	J-GAAP
Jan - Sep, 2025	2,311	-344	-426	-568	-24.3	ー	Nov 14, 2025	J-GAAP
YoY	-2.4%	-1,174.1%	-84.4%	-67.6%	-54.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	406	-229	-257	-206	-9.6	-56.4	Feb 14, 2024	J-GAAP
Jan - Mar, 2024	648	44	-77	-78	-3.6	6.8	May 15, 2024	J-GAAP
Apr - Jun, 2024	763	-198	-200	-245	-11.4	-26.0	Aug 14, 2024	J-GAAP
Jul - Sep, 2024	958	127	46	-16	-0.7	13.3	Nov 14, 2024	J-GAAP
Oct - Dec, 2024	738	-186	-130	-156	-7.2	-25.2	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	965	93	29	-5	-0.2	9.6	May 15, 2025	J-GAAP
Apr - Jun, 2025	570	-283	-320	-349	-15.3	-49.6	Aug 14, 2025	J-GAAP
Jul - Sep, 2025	776	-154	-135	-214	-9.2	-19.8	Nov 14, 2025	J-GAAP
YoY	-19.0%	－	－	-1,237.5%	-1,136.5%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	534	-46.3	Available in future release
Jan - Mar, 2021	655	+432.5
Apr - Jun, 2021	665	+167.1
Jul - Sep, 2021	303	+50.7
Oct - Dec, 2021	1,153	+115.9
Jan - Mar, 2022	339	-48.2
Apr - Jun, 2022	1,108	+66.6
Jul - Sep, 2022	457	+50.8
Oct - Dec, 2022	1,014	-12.1
Jan - Mar, 2023	370	+9.1
Apr - Jun, 2023	644	-41.9
Jul - Sep, 2023	481	+5.3
Oct - Dec, 2023	406	-60.0
Jan - Mar, 2024	648	+75.1
Apr - Jun, 2024	763	+18.5
Jul - Sep, 2024	958	+99.2
Oct - Dec, 2024	738	+81.8
Jan - Mar, 2025	965	+48.9
Apr - Jun, 2025	570	-25.3
Jul - Sep, 2025	776	-19.0	-154	－	-135	－	-9.2	-1,214.3

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,153	670	751	982	72.5
Fiscal Year	Dec, 2021	Jun, 2022	Jun, 2022	Mar, 2014	Mar, 2014

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2022	261.65	87.7	6,257	5,488	773	0.04	Feb 14, 2023	J-GAAP
Dec, 2023	281.87	88.7	6,871	6,094	449	0.06	Feb 14, 2024	J-GAAP
Dec, 2024	253.83	57.4	9,655	5,543	-45	0.62	Feb 14, 2025	J-GAAP
Jan - Sep, 2025	ー	63.0	9,518	5,999	-614	0.51	Nov 14, 2025	J-GAAP

RaQualia Pharma Inc.(4579) Financial Results